CyFlow™ CD31 PerCP

CyFlow™ CD31 PerCP
Laser: Blue, Green
Target Species: Human
Antigen: CD31
Field of Interest: Immunophenotyping
Clone: MEM-05
Regulatory Status: RUO
Alternative Name: endoCAM, PECA1, PECAM-1
Application: Flow cytometry
Format/Fluorochrome: PerCP
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 678 nm
Excitation Maximum: 482 to 490 nm
Isotype: IgG1
Product number: AS946732

For Research Use Only

$265.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA V Quantity 100 tests Immunogen Leukocytes of a patient suffering... more
CyFlow™ CD31 PerCP
HLDA WorkshopHLDA V
Quantity100 tests
ImmunogenLeukocytes of a patient suffering from LGL-type Leukemia
SpecifityThe mouse monoclonal antibody MEM-05 recognizes CD31 antigen, a 130-140 kDa type I transmembrane glycoprotein expressed on monocytes, platelets, granulocytes, endothelial cells and stem cells of the myeloid lineage.
Background InformationCD31 (PECAM-1; platelet endothelial cell adhesion molecule-1) is an inhibitory coreceptor involved in regulation of T cell and B cell signaling by a dual immunoreceptor tyrosine-based inhibitory motif (ITIM) that upon associated kinases-mediated phosphorylation provide docking sites for protein-tyrosine phosphatases. CD31 is expressed ubiquitously within the vascular compartment and is located mainly at junctions between adjacent cells. N-terminal Ig-like domain of CD31 is responsible for its homophilic binding, which plays an important role in cell-cell interactions. CD31 is a multifunctional molecule with diverse roles in modulation of integrin-mediated cell adhesion, transendothelial migration, angiogenesis, apoptosis, negative regulation of immunoreceptor signaling, autoimmunity, macrophage phagocytosis, IgE-mediated anaphylaxis and thrombosis. It is one of key regulatory molecules in vascular system.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Prager E, Staffler G, Majdic O, Saemann M, Godar S, Zlabinger G, Stockinger H: Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor:ligand pathway in T cells. J·Immunol. 2001·Feb·15; 166(4):2364‑71. <·PMID:·11160294·> | Newman DK, Hamilton C, Newman PJ: Inhibition of antigen‑receptor signaling by Platelet Endothelial Cell Adhesion Molecule‑1 (CD31 requires functional ITIMs, SHP‑2, and p56(lck). Blood. 2001·Apr·15; 97(8):2351‑7. <·PMID:·11290597·> | Wilkinson R, Lyons AB, Roberts D, Wong MX, Bartley PA, Jackson DE: Platelet endothelial cell adhesion molecule‑1 (PECAM‑1/CD31 acts as a regulator of B‑cell development, B‑cell antigen receptor (BCR)‑mediated activation, and autoimmune disease. Blood. 2002·Jul·1; 100(1):184‑9. <·PMID:·12759520·> | Jackson DE: The unfolding tale of PECAM‑1. FEBS·Lett. 2003·Apr·10; 540(1‑3):41821. <·PMID:·12681475·> | Wee JL, Jackson DE: The Ig‑ITIM superfamily member PECAM‑1 regulates the "outside‑in" signaling properties of integrin alpha(IIb)beta3 in platelets. Blood. 2005·Dec·1; 106(12):3816‑23. <·PMID:·16081692·> | Woodfin A, Voisin MB, Nourshargh S: PECAM‑1: a multi‑functional molecule in inflammation and vascular biolog. Arterioscler·Thromb·Vasc·Biol. 2007·Dec; 27(12):2514‑23. <·PMID:·17872453·> | Wong MX, Hayball JD, Jackson DE: PECAM‑1‑regulated signalling thresholds control tolerance in anergic transgenic B‑cells. Mol·Immunol. 2008·Mar; 45(6):1767‑81. <·PMID:·17977600·> | Cârţână T, Săftoiu A, Gruionu LG, Gheonea DI, Pirici D, Georgescu CV, Ciocâlteu A, Gruionu G: Confocal laser endomicroscopy for the morphometric evaluation of microvessels in human colorectal cancer using targeted anti‑CD31 antibodies. PLoS·One. 2012; 7(12):e52815. <·PMID:·23285192·>

Article successfully added.